Skip to main content
Fig. 2 | Clinical Sarcoma Research

Fig. 2

From: Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation

Fig. 2

PET/CT imaging prior to (ad) and after 10 weeks (eh) of sunitinib therapy. Prior to treatment, whole body PET (a) revealed a large hypermetabolic lesion in the dome of the liver, a PET-avid sub-cm L hepatic lesion, and hypermetabolic activity in the abdominal wall near the site of previous surgical resection. On cross sectional CT imaging (b) the large hepatic lesion measured 5.9 × 5.1 cm in maximal dimension, and the corresponding area on PET imaging (c) and fused PET/CT (d) revealed an SUVmax of 8.4. Both liver lesions were no longer detectable on repeat imaging (eh), and the surgical site hypermetabolic activity decreased (e), consistent with resolving post-operative changes

Back to article page